https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47964 70 mm Hg associated with worse outcomes]), right atrial volume index (pinteraction=0·012 [≥29·7 mL/m2, worse outcomes]), and sex (pinteraction=0·02 [men, worse outcomes]). There were no differences in the composite safety endpoint between the two groups (n=116 [38%] for shunt device vs n=97 [31%] for sham procedure; p=0·11). Interpretation: Placement of an atrial shunt device did not reduce the total rate of heart failure events or improve health status in the overall population of patients with heart failure and ejection fraction of greater than or equal to 40%. Funding: Corvia Medical.]]> Mon 13 Feb 2023 15:45:01 AEDT ]]> Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54596 Mon 04 Mar 2024 08:42:35 AEDT ]]>